Unknown

Dataset Information

0

Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.


ABSTRACT: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, and although new therapeutic approaches have been recently evaluated, overall patient survival is still poor. Thus, new effective and selective clinical treatments are urgently needed. An analysis of data from large-scale, high-throughput drug screening cell line projects identified Bosutinib, a Src/Abl inhibitor that is currently used for the treatment of chronic myelogenous leukemia, as a candidate drug to treat HNSCC. Using a panel of HNSCC-derived cell lines, we found that treatment with Bosutinib reduced cell proliferation and induced apoptosis of sensitive cell lines. The drug rapidly inhibited Src and EGFR (epidermal growth factor receptor) phosphorylation, and sensitivity to Bosutinib was correlated with the activation status of EGFR. Similar findings were observed in in vivo xenograft assays using HNSCC derived cells. Moreover, in the presence of mutations in PIK3CA, the combination of Bosutinib with the PI3K? inhibitor Alpelisib showed a synergistic effect. These results suggest that Bosutinib could be a new effective drug for the treatment of HNSCC, particularly in tumors with high EGFR activity. Its combination with Alpelisib could especially benefit patients bearing activating mutations of PIK3CA.

SUBMITTER: Segrelles C 

PROVIDER: S-EPMC6073167 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.

Segrelles Carmen C   Contreras David D   Navarro Elena M EM   Gutiérrez-Muñoz Carmen C   García-Escudero Ramón R   Paramio Jesús M JM   Lorz Corina C  

International journal of molecular sciences 20180621 7


Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, and although new therapeutic approaches have been recently evaluated, overall patient survival is still poor. Thus, new effective and selective clinical treatments are urgently needed. An analysis of data from large-scale, high-throughput drug screening cell line projects identified Bosutinib, a Src/Abl inhibitor that is currently used for the treatment of chronic myelogenous leukemia, as a candidate drug to  ...[more]

Similar Datasets

| S-EPMC7020369 | biostudies-literature
| S-EPMC2770888 | biostudies-literature
| S-EPMC8236611 | biostudies-literature
| S-EPMC7028269 | biostudies-literature
| S-EPMC5674107 | biostudies-literature
| S-EPMC7061757 | biostudies-literature
| S-EPMC4299638 | biostudies-literature
| S-EPMC5522587 | biostudies-literature
| S-EPMC3944644 | biostudies-literature
| S-EPMC4496210 | biostudies-literature